Suggested remit: To appraise the clinical and cost effectiveness of elinzanetant within its marketing authorisation for treating moderate to severe vasomotor symptoms associated with menopause.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6359
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6359:
- 22 July 2026 - 19 August 2026
Project Team
- Project lead
- scopingta@nice.org.uk
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 July 2026 | In progress. Scoping commencing |
| 08 April 2026 | Appraisal anticipated to begin late September 2026 - Note added to the project documents |
| 26 July 2024 | Note - Note added to the project documents |
| 12 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 12 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual